Document 1090
 DOCN  M9471090
 TI    Novel combination chemotherapy for HIV-related non-Hodgkin's lymphoma
       (HIV-NHL) (Meeting abstract).
 DT    9409
 AU    Sawka C; Shepherd F; Brandwein J; Berinstein N; Singer J; Canadian HIV
       Trials Network, Vancouver, Canada
 SO    Proc Annu Meet Am Soc Clin Oncol; 13:A13 1994. Unique Identifier :
       AIDSLINE ICDB/94600010
 AB    Conventional-dose chemotherapy is poorly tolerated in HIV-NHL; even
       low-dose programs including our half-dose weekly drug program (Leukemia
       and Lymphoma 1992, 8:213-220) have been associated with significant
       febrile neutropenia rates. We designed a novel chemotherapy program to
       attempt to reduce this complication while maintaining efficacy. The
       program consisted of six 21 day cycles of: etoposide 50 mg po od d1-14,
       vincristine 2 mg iv d1, prednisone 100 mg po d 1-4, ara-c 50 mg IT d1.
       Mitoxantrone 6 mg/m2 was given iv d1 on cycles 1,3,5; cyclophosphamide
       300 mg/m2 was given iv d1 on cycles 2,4,6. Septra or aerosol pentamidine
       was given throughout treatment and anti-retrovirals were started at
 DE    Adult  Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE
       Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
       Cytarabine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  Dose-Response
       Relationship, Drug  Drug Administration Schedule
       Etoposide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  Human  Lymphoma,
       AIDS-Related/*DRUG THERAPY/MORTALITY  Male  Mitoxantrone/ADMINISTRATION
       & DOSAGE/ADVERSE EFFECTS  Prednisone/ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS  Survival Rate  Vincristine/ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).